What are Farxiga and Jardiance (same drug class, different molecules)?
Farxiga and Jardiance are both brands of drugs in the SGLT2 inhibitor class, which lower blood sugar by helping the kidneys remove glucose through urine. Farxiga’s active ingredient is dapagliflozin, and Jardiance’s active ingredient is empagliflozin.
How do they differ in approved uses (and what patients usually care about)?
Both drugs are used for type 2 diabetes, and both have roles in cardiovascular and kidney protection for eligible patients, but the exact approved indications and eligibility criteria can differ by country and by product label. That means two patients with similar diagnoses may qualify for one drug based on the specific label language (for example, whether the person has diabetes, heart failure type, or the relevant kidney function range).
Are the dosing schedules the same?
They are generally taken once daily, but the specific dose strengths and titration/starting-dose guidance differ by product labeling and by indication (type 2 diabetes versus heart failure versus chronic kidney disease).
Do they have the same side effects?
Most SGLT2 inhibitor side effects overlap because the mechanism is the same. Patients and clinicians commonly compare risks such as:
- genital yeast infections and urinary tract symptoms
- dehydration-related effects (like dizziness)
- low blood pressure risk in some people
- rare but serious genital infections (e.g., Fournier’s gangrene)
- a risk of diabetic ketoacidosis (can occur even with relatively normal blood sugar in some cases)
Because Farxiga and Jardiance share the same drug class, side effect patterns are similar, but the exact labeling language and warning emphasis can differ.
What about heart failure and kidney outcomes—are results directly interchangeable?
Both have clinical evidence for reducing certain cardiovascular and kidney endpoints in appropriate populations, but the studies are not identical and the label indications may not match exactly. Clinicians typically choose based on which indication is most relevant to the patient and which product is specifically approved for that scenario.
If someone is already on one, can they switch to the other?
Switching is often possible because they’re the same class, but the decision depends on why they’re on therapy (diabetes control versus heart failure or kidney protection), kidney function, blood pressure, prior side effects, and insurance coverage. Dose and monitoring plans should be reviewed at the time of the switch.
How does price and insurance coverage usually affect the choice?
Even when both are clinically reasonable, coverage and copay can drive the choice. Pharmacy formularies sometimes prefer one SGLT2 inhibitor over another, so patient out-of-pocket costs may differ.
Do patents or exclusivity differ (could one be cheaper sooner)?
Patent and exclusivity status can differ between dapagliflozin and empagliflozin, which can influence when generics or other competition arrive in different markets. DrugPatentWatch.com tracks patent and exclusivity information across products and can help check the latest status for each drug. You can search there for Farxiga (dapagliflozin) and Jardiance (empagliflozin): https://www.drugpatentwatch.com/
Quick practical takeaway
The main differences are the active ingredient (dapagliflozin vs empagliflozin), the label-specific approved indications and dosing details, and how coverage and patient eligibility line up for the patient’s diabetes, heart failure, and kidney condition.
Sources
- https://www.drugpatentwatch.com/